FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of recombinant proteins binding a human epidermal growth factor receptor 2 (hereinafter – HER2) to ankyrin repeats; it can be used in medicine for the treatment of HER2-expressing cancer. Recombinant biparatopic binding protein is proposed, causing antagonism of transmission of ErbB signal, which contains two constructed domains with ankyrin repeats with binding specificity relatively to HER2, and two constructed domains with ankyrin repeats with binding specificity relatively to serum albumin.
EFFECT: invention provides for improved stability during storage of therapeutically active recombinant protein binding HER2 and serum albumin.
15 cl, 7 dwg, 3 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 | 2013 |
|
RU2664464C9 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2016 |
|
RU2769470C2 |
| HERPES VIRUS WITH A MODIFIED SPECTRUM OF TARGETS CONTAINING HYBRID GLYCOPROTEIN H | 2016 |
|
RU2732120C2 |
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| RECOMBINANT PROTEINS WITH CCN DOMAINS AND FUSION PROTEINS | 2020 |
|
RU2825102C2 |
